Melanoma circulating tumor cells: Benefits and challenges required for clinical application

G. Marsavela, C. A. Aya-Bonilla, M. E. Warkiani, E. S. Gray, M. Ziman

    Research output: Contribution to journalShort survey

    12 Citations (Scopus)

    Abstract

    The implementation of novel therapeutic interventions has improved the survival rates of melanoma patients with metastatic disease. Nonetheless, only 33% of treated cases exhibit long term responses. Circulating tumor cell (CTC) measurements are currently of clinical value in breast, prostate and colorectal cancers. However, the clinical utility of melanoma CTCs (MelCTCs) is still unclear due to challenges that appear intrinsic to MelCTCs (i.e. rarity, heterogeneity) and a lack of standardization in their isolation, across research laboratories. Here, we review the latest developments, pinpoint the challenges in MelCTC isolation and address their potential role in melanoma management.

    Original languageEnglish
    Pages (from-to)1-8
    Number of pages8
    JournalCancer Letters
    Volume424
    DOIs
    Publication statusPublished - 28 Jun 2018

    Fingerprint Dive into the research topics of 'Melanoma circulating tumor cells: Benefits and challenges required for clinical application'. Together they form a unique fingerprint.

  • Cite this